- Phosphodiesterase type 5 inhibitor differentiation based on selectivity pharmacokinetic and efficacy profiles
- Role of the cardiologist clinical aspects of managing erectile dysfunction
- Erectile dysfunction management update
- Levitra a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction
- New drugs of 2003
- Pharmacokinetics pharmacodynamics and efficacy of phosphodiesterase type 5 inhibitors
- Therapeutic options for patients returning to sexual activity
- The efficacy and safety of flexible-dose Levitra levitra in a broad population of European men
- Treatment of erectile dysfunction
- Gateways to clinical trials
- Drug Interactions Among the Antiretrovirals
- Erectile dysfunction Epidemiology physiology etiology diagnosis and therapy]
- Spotlight on Levitra in erectile dysfunction
- Drug approval highlights for 2003
- Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy
- Levitra treatment for erectile dysfunction
- Switching patients with erectile dysfunction from sildenafil citrate to tadalafil results of a European multicenter open-label study of patient preference
- Novel PDE5 inhibitors for the treatment of male erectile dysfunction
- Pro-erectile effect of Levitra in vitro experiments in rabbits and in vivo comparison with sildenafil in rats
- Levitra a review of its use in erectile dysfunction
- Medication of the month Levitra Levitra]
- Levitra a new approach to the treatment of erectile dysfunction
- Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists
- Overview of phosphodiesterase 5 inhibition in erectile dysfunction
- Gateways to clinical trials
- Drug therapy of erectile dysfunction--the current status]
- Phosphodiesterase type 5 inhibitors a biochemical and clinical correlation survey
- Safety and efficacy of Levitra for the treatment of men with erectile dysfunction after radical retropubic prostatectomy
- Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules
- Efficacy and tolerability of Levitra for treatment of erectile dysfunction in patient subgroups
- Hypogonadism and erectile dysfunction the role for testosterone therapy
- Phosphodiesterase 5 inhibitors in male sexual dysfunction
- Erectile dysfunction and phosphodiesterase type 5 inhibitors]
- Erectile dysfunction in the cardiac patient how common and should we treat
- Gateways to clinical trials
- Conservative treatment of erectile dysfunction]
- PDE-5 inhibition and sexual response pharmacological mechanisms and clinical outcomes
- New treatment options for erectile dysfunction Pharmacologic and nonpharmacologic options]
- Gateways to clinical trials
- Levitra enhances clitoral and vaginal blood flow responses to pelvic nerve stimulation in female dogs
- Levitra reverses erectile dysfunction induced by paroxetine in rats
- Gateways to clinical trials March 2003
- Effects of medical or surgical castration on erectile function in an animal model
- How effective are PDE-5 inhibitors]
- Effective treatment of erectile dysfunction with Levitra
- Sustained efficacy and tolerability of Levitra a highly potent selective phosphodiesterase type 5 inhibitor in men with erectile dysfunction results of a randomized double-blind 26-week placebo-controlled pivotal trial
- Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of Levitra an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction
- Pharmacology of phosphodiesterase 5 inhibitors
- Levitra a new phosphodiesterase type 5 inhibitor in the treatment of erectile dysfunction in men with diabetes a multicenter double-blind placebo-controlled fixed-dose study
- Pharmacological management of erectile dysfunction
